Antibodies against MIP-1α, MIP-1β chemokines inhibit fusion enhancement of MDMs with X4 envelope-expressing cells when added to the IFN-γ/IL-6–treated MDMs
| Treatment5-151 . | Antibodies5-152 . | No. of syncytia5-150 . | |
|---|---|---|---|
| IIIB . | JR-FL . | ||
| None | None | 9 ± 1 | 156 ± 1 |
| a-MIP-1α; a-MIP-1β | a-MIP-1α; a-MIP-1β | 8 ± 2 | 161 ± 20 |
| IFN-γ | None | 33 ± 3 | 37 ± 5 |
| IFN-γ | a-MIP-1α; a-MIP-1β | 5 ± 1 | 127 ± 17 |
| IL-6 | None | 32 ± 5 | 109 ± 9 |
| IL-6 | a-MIP-1α; a-MIP-1β | 2 ± 1 | 183 ± 6 |
| Treatment5-151 . | Antibodies5-152 . | No. of syncytia5-150 . | |
|---|---|---|---|
| IIIB . | JR-FL . | ||
| None | None | 9 ± 1 | 156 ± 1 |
| a-MIP-1α; a-MIP-1β | a-MIP-1α; a-MIP-1β | 8 ± 2 | 161 ± 20 |
| IFN-γ | None | 33 ± 3 | 37 ± 5 |
| IFN-γ | a-MIP-1α; a-MIP-1β | 5 ± 1 | 127 ± 17 |
| IL-6 | None | 32 ± 5 | 109 ± 9 |
| IL-6 | a-MIP-1α; a-MIP-1β | 2 ± 1 | 183 ± 6 |
MIP indicates macrophage inflammatory protein; MDMs, monocyte-derived macrophages; IFN-γ, interferon γ; IL-6, interleukin 6.
Syncytia were scored after 18 hours of coculture of the macrophages and the effector cells: TF228 cells expressing IIIB envelope or 12E1 cells infected with recombinant vaccinia virus expressing R5 envelope (vCB28, JR-FL). Data represent 2 experiments.
MDMs were treated with cytokines for the last 24 hours of the culture.
Anti–MIP-1α and anti–MIP-1β antibodies were used at 2 μg/mL. Antibodies were added to MDMs simultaneously with cytokines.